Novavax
Big pharma — Maximum earnings, minimum responsibilities

The COVID-19 pandemic has again exposed the true nature of capitalism with profit being the primary driver irrespective of the rising inequalities

Could Novavax’s COVID vaccine address some challenges in the current vaccination process?

Newsclick’s Prabir Purkayastha and immunologist Dr. Satyajit Rath discuss Covavax, the protein subunit-based vaccine manufactured by the US manufacturer Novavax

Covaxin trials: What 81% “interim efficacy” means

Bharat Biotech has claimed in a press release that its Covid-19 vaccine candidate, Covaxin, showed 81% efficacy in the “first interim analysis” of phase-3 trials.

    × To Subscribe